Press Room

Visit our press room for current and past releases about our company.
May 14, 2013

Vince and Associates Clinical Research Joins the Altasciences Group

(Laval, Québec, Canada May 14, 2013) – The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.

vince_and_associates_press_release_may_14.pdf
March 24, 2013

SQI Diagnostics and Algorithme Pharma Provide Update on Multiplex Heparin Immunogenicity Assay

Collaborative results recently presented at the 14th Annual Immunogenicity for Biotherapeutics Conference in Baltimore 18-20 March

TORONTO - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”), and Algorithme Pharma (“Algorithme”) today announced that they have completed the multiplexed proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) biosimilar compounds using SQI’s Ig_PLEX™ multiplexing technology.

February 13, 2013

Lab Bio-Medic, Algorithme Pharma Sign Partnership

Montreal, February 14, 2013 – Lab Bio-Medic and Algorithme Pharma are pleased to announce that they have signed a partnership agreement for the delivery of biomedical analysis required as part of clinical research projects conducted on behalf of pharmaceutical and biotech customers of this world leader in the conduct of Phase I / IIa and bioequivalence clinical trials.  

January 27, 2013

Algorithme Pharma and SQI Diagnostics to Develop Multiplex Heparin Immunogenicity Assay

Laval, Quebec, January 25, 2013 – Algorithme Pharma and SQI Diagnostics’ (“SQI”) announced that they are using SQI’s Ig_PlexTM multiplexing technology to develop a multiplex proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) compounds.

February 07, 2012

Critical Outcome Technologies Inc. announced today it has engaged Algorithme Pharma Inc.

London, Ontario: Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)announced today that it has engaged Algorithme Pharma Inc. (Algorithme) of Montreal, Canada, aninternationally recognized contract research organization, to develop and validate the final quantitativemethod to be used for preclinical and Phase 1 studies for COTI‐2. 

Pages